Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12232520 | 0.91 | CHRM2 (0.48) | CCR1CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL12232281 | 0.90 | MAOB (0.40) | CCR1LRRK2MAOB | |
| SCHEMBL12232285 | 0.88 | ADAMTS5 (0.44) | CCR1ADAMTS5MMP2MAOB | |
| SCHEMBL12233867 | 0.86 | CCR1 (0.40) | CCR1CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL12232682 | 0.85 | CHRM2 (0.47) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL12233840 | 0.85 | ADAMTS5 (0.51) | ADAMTS5MMP2MMP14 | |
| SCHEMBL12232523 | 0.82 | LRRK2 (0.42) | LRRK2ADAMTS5 | |
| SCHEMBL12232806 | 0.81 | CHRM1 (0.41) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL12232803 | 0.78 | MMP2 (0.48) | CHRM2CHRM5CHRM1CHRM3ADAMTS5 | |
| SCHEMBL12232679 | 0.77 | ALDH1A1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251212-A1 | PIPERAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251212-A1 | PIPERAZINE DERIVATIVES | GRIN2C, NR2C2, GRIN3A | CCR1 767/4885CHRM2 108/4885CHRM5 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.